H 2 O 2 Self-Supplying and GSH-Depleting Nanocatalyst for Copper Metabolism-Based Synergistic Chemodynamic Therapy and Chemotherapy
Molecular Pharmaceutics · 2023
DOI: 10.1021/acs.molpharmaceut.2c00937 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Zhaomin Tang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of New Energy and Materials, Southwest Petroleum University, Chengdu 610500, China. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, Dalian Institute of Chemical Physics, Youth Innovation Promotion Association of the Chinese Academy of Sciences.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Chemodynamic therapy (CDT) that involves the use of Fenton catalysts to convert endogenous hydrogen peroxide (H2O2) to hydroxyl radicals (·OH) constitutes a promising strategy for cancer therapy; however, insufficient endogenous H2O2 and glutathione (GSH) overexpression render its efficiency unsatisfactory. Herein, we present an intelligent nanocatalyst that comprises copper peroxide nanodots and DOX-loaded mesoporous silica nanoparticles (MSNs) (DOX@MSN@CuO2) and can self-supply exogenous H2O2 and respond to specific tumor microenvironments (TME). Following endocytosis into tumor cells, DOX@MSN@CuO2 initially decomposes into Cu2+ and exogenous H2O2 in the weakly acidic TME. Subsequently, Cu2+ reacts with high GSH concentrations, thereby inducing GSH depletion and reducing Cu2+ to Cu+ Next, the generated Cu+ undergoes Fenton-like reactions with exogenous H2O2 to accelerate toxic ·OH production, which exhibits a rapid reaction rate and is responsible for tumor cell apoptosis, thereby enhancing CDT. Furthermore, the successful delivery of DOX from the MSNs achieves chemotherapy and CDT integration. Thus, this excellent strategy can resolve the problem of insufficient CDT efficacy due to limited H2O2 and GSH overexpression. Integrating H2O2 self-supply and GSH deletion enhances CDT, and DOX-induced chemotherapy endows DOX@MSN@CuO2 with effective tumor growth-inhibiting properties alongside minimal side effects in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of New Energy and Materials, Southwest Petroleum University, Chengdu 610500, China.
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.
- Department of Ultrasound, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China School of Medicine, Chengdu 610500, China.
- Department of Ophthalmology, The Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.
ORCID-Profile: Zhaomin Tang, Huangzhao Wei
Förderung
- Ministry of Science and Technology of the People's Republic of China
- Dalian Institute of Chemical Physics
- Youth Innovation Promotion Association of the Chinese Academy of Sciences
- National Natural Science Foundation of China
- Southwest Petroleum University
- Sichuan International Science and Technology Cooperation Base
Zitieren
APA
Tang, Z., Jiang, S., Tang, W., He, Q., Wei, H., Jin, C., Wang, S., & Zhang, H. (2023). H 2 O 2 Self-Supplying and GSH-Depleting Nanocatalyst for Copper Metabolism-Based Synergistic Chemodynamic Therapy and Chemotherapy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.2c00937
Vancouver
Tang Z, Jiang S, Tang W, He Q, Wei H, Jin C, et al. H 2 O 2 Self-Supplying and GSH-Depleting Nanocatalyst for Copper Metabolism-Based Synergistic Chemodynamic Therapy and Chemotherapy. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.2c00937
BibTeX
@article{Tang2023,
author = {Tang, Zhaomin and Jiang, Shuting and Tang, Wanlan and He, Qian and Wei, Huangzhao and Jin, Chengyu and Wang, Shuai and Zhang, Hui},
title = {H 2 O 2 Self-Supplying and GSH-Depleting Nanocatalyst for Copper Metabolism-Based Synergistic Chemodynamic Therapy and Chemotherapy},
journal = {Molecular Pharmaceutics},
year = {2023},
doi = {10.1021/acs.molpharmaceut.2c00937}
}
EUVIMED